Rosai-Dorfman disease with MAP2K1 mutation: therapeutic response to MEK inhibition after failure of conventional therapy
{{output}}
Rosai-Dorfman disease (RDD) is a rare histiocytic disorder, usually benign but may follow an aggressive and treatment-refractory course in a subset of patients. Somatic mutations involving the MAPK/ERK pathway, particularly KRAS and MAP2K1, have been increasin... ...
